Source: FDA
Area: News
The US FDA has approved aflibercept (Eylea®) for the treatment of wet (neovascular) age-related macular degeneration (AMD). Aflibercept is administered as an intravitreal injection (given by an ophthalmologist) every 4-8 weeks.
The approval was based on the results from two clinical trials (n=2,412) that showed aflibercept to be non-inferior to ranibizumab in maintaining or improving visual acuity (primary endpoint) after one year of treatment.
Uncategorized